NCT04770415 is a clinical trial in Ophthalmic Manifestations, sponsored by Shrouk Shaban Bakr.

Who is sponsoring NCT04770415?

NCT04770415 is sponsored by Shrouk Shaban Bakr.

What condition does NCT04770415 study?

NCT04770415 studies Ophthalmic Manifestations.

Is NCT04770415 still recruiting?

NCT04770415 is currently status unknown. Last updated 25 February 2021.

Last reviewed 2021-02-25 · How we verify

NCT04770415

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ophthalmic Manifestations of Patients With Mucopolysaccharidosis

Status unknown Last updated 25 February 2021

What this trial tests

trial in Ophthalmic Manifestations in 28 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
1 April 2023

1 April 2023

Quick facts

Lead sponsor	Shrouk Shaban Bakr
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	28
Start date	1 April 2021
Primary completion	1 April 2023
Estimated completion	1 April 2023
Sites	1 location across Egypt

Conditions studied

Ophthalmic Manifestations — all drugs for Ophthalmic Manifestations →

Sponsor

Shrouk Shaban Bakr

Who can join

Under 18, any sex, with Ophthalmic Manifestations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mucopolysaccharidosis (MPSs) are a group of disorders caused by inherited defects in lysosomal enzymes resulting in widespread intra- and extra-cellular accumulation of glycosaminoglycan(1,2). They have been subdivided according to enzyme defect and systemic manifestations and include MPS IH (Hurler)(3) , MPS IS (Scheie), MPS IH/S (Hurler/Sheie), MPS II(4,5) (Hunter), MPS III (Sanfilippo)(6) , MPS IV (Morquio)(7,8), MPS VI (Maroteaux-Lamy)(9), MPS VII (Sly)(10,11) and MPS IX (Natowicz)(12). Mucopolysaccharidosis have a spectrum of systemic manifestations, including airway and respiratory compromise, skeletal deformities, intellectual and neurological impairment, cardiac abnormalities, gastrointestinal problems and ocular manifestations(13). Ocular manifestation are common in the mucopolysaccharidosis and may result in significant visual impairment(14). Corneal opacification of varying severity is frequently seen, as well as retinopathy, optic nerve swelling and atrophy, ocular hypertension, and glaucoma(14). New treatment modalities for the systemic manifestations of the mucopolysaccharidosis include bone marrow transplant and enzyme replacement therapy have resulted in an improved prognosis in many cases(15).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04770415 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shrouk Shaban Bakr
Last refreshed: 25 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04770415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing